title: Virus genotype 1b and long-term response to interferon alpha monotherapy in children with chronic hepatitis C.
abstract: Interferon alpha (IFN-alpha) remains the basic modality in the treatment of chronic hepatitis C in children, but the effects of therapy are still unsatisfactory. The aim of this study was to evaluate parameters linked to IFN-alpha response within a 2-year period. Human C virus (HCV) infected children (n=34) were subdivided into IFN-treated (n=20) and IFN-untreated (n=14 control) groups. The IFN-treated group received a dosage 3 MU of IFN-alpha three times a week for 24 weeks. Liver biopsy was performed in all IFN-treated children and the HCV genotype was determined before the start of the study. Patients were sequentially screened for alanine transaminase (ALT) activity and tested for the presence of HCV-RNA in serum. All patients had either mild persistent or moderate active hepatitis, which was diagnosed from the liver biopsy. In the IFN-treated group ALT normalisation was observed by the end of treatment in 9/20 patients, but after 6 months 10 patients (50%) had sustained ALT normalisation and in 4 of them the virus was eliminated. They continued to show these features up to the end of the observation period (2 years). Eighteen out of 24 children tested had 1b genotype of virus. Out of 10 responders, all patients who were clear of HCV had the 1b genotype. The median age of responders (6.0, range 3.8-16) was significantly lower than non-responders (14.0, range 4-15) In the control group none of the children were clear of HCV-RNA.
  
  
  CONCLUSIONS
  The negative predictive effect of HCV genotype 1b in the course of IFN-alpha treatment may be not valid in children and other features have to be taken into account in the assessment of the efficacy of therapy.
authors.affiliation: Department of Infectious Diseases and Child Neurology, Institute of Paediatrics, Karol Marcinkowski University of Medical Sciences, 27/33 Szpitalna Strasse, 60-572, Poznań, Poland. iwonalisewska@poczta.onet.pl
authors.forename: Iwona
authors.initials: I
authors.lastname: Mozer-Lisewska
authors.forename: Wojciech
authors.initials: W
authors.lastname: Słuzewski
authors.forename: Khaled
authors.initials: K
authors.lastname: Ali Youseif
authors.forename: Magdalena
authors.initials: M
authors.lastname: Figlerowicz
authors.forename: Arleta
authors.initials: A
authors.lastname: Kowala-Piaskowska
mesh_terms: D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000235:genetics* / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008111:Liver Function Tests; D008134:Long-Term Care; D008297:Male; D011336:Probability; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis; D012016:Reference Values; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D016898:Interferon-alpha; D012367:RNA, Viral